Opportunity Information: Apply for RFA AI 14 007
Apply for RFA AI 14 007
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Human Immunology Project Consortium (U19)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Feb 3, 2014 and posted on Feb 3, 2014.
- Applicants must submit their applications by Sep 18, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $15,700,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $2,120,000.00 in funding.
- Eligible applicants include: Native American tribal organizations (other than Federally recognized tribal governments) Small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Independent school districts State governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public housing authorities/Indian housing authorities For profit organizations other than small businesses Special district governments County governments Private institutions of higher education City or township governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Human Immunology Project Consortium (HIPC) U19 opportunity (Funding Opportunity Number RFA-AI-14-007) is an NIH cooperative agreement designed to build and support a coordinated network of research groups focused on comprehensive profiling of human immune responses in non-HIV infectious disease settings. The program is aimed at applicants from a single institution or multi-institution consortia that can contribute well-characterized human cohorts, deep clinical and demographic data, and modern high-throughput immunology and systems biology platforms. The central idea is to move beyond isolated measurements of a few immune markers and instead generate broad, integrated profiles that capture how the immune system behaves across different people and conditions, and to do so in a way that allows comparisons across studies within the consortium.
Projects are expected to investigate the human immune system in one or more of three main contexts: immune responses during infection or in the period following infection; immune responses measured before and after vaccination against an infectious disease; and immune responses measured before and after administration of vaccine adjuvants that specifically engage innate immune pathways. In practice, this means proposals should be anchored in real-world human immunology, with clear timepoints and clinical context, and should collect specimens and data in a way that enables longitudinal tracking of immune changes and clinical outcomes. The FOA emphasizes detailed clinical phenotyping, meaning that laboratory profiling is meant to be paired with strong clinical characterization of participants (such as disease severity, symptom trajectories, prior exposures, vaccine history, or other medically relevant variables), so immune patterns can be interpreted against meaningful health endpoints.
A core goal of the consortium is to capitalize on advances in immune profiling technologies and computational approaches. While the FOA does not limit applicants to specific platforms, the intent is to use high-throughput, systems-level methods that can capture diverse immune features at scale and with enough standardization to support cross-cohort analyses. This typically includes strategies that measure multiple layers of immune biology (for example, cellular composition and phenotype, gene expression programs, cytokine and chemokine patterns, antibody features, and other molecular readouts), followed by integrative analyses to find shared and distinct response patterns across individuals and study settings. The longer-term deliverable is the development of molecular signatures or immune "fingerprints" that can classify response types and correlate with outcomes of infection or vaccination, such as protection, susceptibility, disease severity, durability of immunity, or adverse responses. In other words, the program is pushing toward predictive and mechanistic immune signatures that are reproducible and useful across populations, not just descriptive datasets.
Mechanistically, this is offered as a cooperative agreement (U19), which signals substantial NIH programmatic involvement compared with a standard research grant. Cooperative agreements commonly require close coordination with NIH staff and active participation in consortium activities, such as shared governance, harmonized protocols, common data elements, standardized assay approaches where feasible, rapid data sharing, and collaborative analyses across sites. Applicants should expect that success in this program depends not only on strong science within their own projects, but also on their ability to operate in a networked environment where interoperability, transparency, and joint planning are central expectations.
From an administrative perspective, the opportunity falls under NIH health research activities and aligns with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). There is no cost sharing or matching requirement. The FOA was posted February 3, 2014, with a closing date of September 18, 2014, and it was archived October 19, 2014. Total estimated funding was listed as $15,700,000, with an award ceiling of $2,120,000, indicating support for multiple awards and multi-component projects typical of U19 consortium structures.
Eligibility is broad across U.S.-based organizations, including public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status, with the usual distinctions), state and local governments, tribal governments and tribal organizations, independent school districts, public housing authorities/Indian housing authorities, special district and regional organizations, and for-profit organizations (including small businesses and other for-profit entities). The announcement explicitly notes eligibility for several institution types such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities, and faith-based or community-based organizations, as well as eligible federal agencies. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply, though foreign components as defined in NIH policy are allowed, which typically means discrete project elements or collaborations occurring outside the U.S. can be included under NIH rules when appropriately justified and approved.
Overall, the HIPC U19 FOA is best understood as a network-building, data-rich human immunology initiative focused on infectious disease and vaccinology (excluding HIV as the primary disease area). It is structured to accelerate discovery of robust immune signatures by combining large-scale profiling technologies with carefully phenotyped cohorts, and by doing so in a coordinated consortium setting where comparability and shared outputs are as important as individual project aims.
FAQs: Human Immunology Project Consortium (HIPC) U19 (RFA-AI-14-007)
What is the HIPC U19 opportunity (RFA-AI-14-007)?
It is an NIH cooperative agreement (U19) intended to build and support a coordinated network of research groups focused on comprehensive profiling of human immune responses in non-HIV infectious disease settings. The emphasis is on generating broad, integrated immune profiles that can be compared across studies within the consortium.
What is the overall purpose of this program?
The program aims to move beyond isolated measurements of a few immune markers and instead produce systems-level, integrated profiles of the human immune response. A key goal is to enable cross-study and cross-cohort comparisons within the consortium so that shared and distinct immune response patterns can be identified across people and conditions.
What types of research contexts are supported?
Projects are expected to investigate human immune responses in one or more of these contexts:
- Immune responses during infection or in the period following infection
- Immune responses measured before and after vaccination against an infectious disease
- Immune responses measured before and after administration of vaccine adjuvants that specifically engage innate immune pathways
Is HIV research included?
The focus is on non-HIV infectious disease settings. The opportunity is described as targeting comprehensive profiling of human immune responses outside of HIV as the primary disease area.
What does “comprehensive profiling†mean in this FOA?
It refers to using modern high-throughput immunology and systems biology platforms to capture diverse immune features at scale, paired with integrative computational analyses. The intent is to generate broad, multi-layer datasets rather than narrowly measuring a small set of immune markers.
Are specific technologies or platforms required?
The FOA does not limit applicants to specific platforms. However, the intent is to use high-throughput, systems-level methods that can capture diverse immune features at scale and with sufficient standardization to support cross-cohort analyses.
What kinds of immune features are expected to be measured?
The FOA describes measuring multiple layers of immune biology. Examples mentioned include cellular composition and phenotype, gene expression programs, cytokine and chemokine patterns, antibody features, and other molecular readouts, followed by integrative analyses.
What role does clinical data play in this opportunity?
Detailed clinical phenotyping is emphasized. Laboratory immune profiling is expected to be paired with strong clinical characterization of participants so immune patterns can be interpreted against meaningful health endpoints.
What examples of clinical characterization are highlighted?
Examples mentioned include disease severity, symptom trajectories, prior exposures, vaccine history, and other medically relevant variables that help interpret immune patterns in clinical context.
Are longitudinal samples and timepoints important?
Yes. Proposals are expected to be anchored in real-world human immunology with clear timepoints and clinical context, collecting specimens and data in a way that enables longitudinal tracking of immune changes and clinical outcomes.
What are the expected deliverables or outcomes from the research?
A longer-term deliverable is the development of molecular signatures or immune “fingerprints†that classify response types and correlate with outcomes of infection or vaccination, such as protection, susceptibility, disease severity, durability of immunity, or adverse responses.
What does it mean that this is a cooperative agreement (U19)?
A cooperative agreement signals substantial NIH programmatic involvement compared with a standard research grant. It typically involves close coordination with NIH staff and active participation in consortium activities.
What kinds of consortium activities should applicants expect?
The FOA describes expectations such as shared governance, harmonized protocols, common data elements, standardized assay approaches where feasible, rapid data sharing, and collaborative analyses across sites.
Does success depend only on the science within an individual project?
No. The FOA emphasizes that success depends on both strong science and the ability to operate effectively in a networked consortium environment where interoperability, transparency, and joint planning are central.
Who can apply: single institutions or consortia?
The program is aimed at applicants from a single institution or multi-institution consortia, particularly those that can contribute well-characterized human cohorts, deep clinical and demographic data, and modern high-throughput immunology and systems biology platforms.
What kinds of applicant organizations are eligible?
Eligibility is broad across U.S.-based organizations, including public and private institutions of higher education; nonprofits (with and without 501(c)(3) status, with the usual distinctions); state and local governments; tribal governments and tribal organizations; independent school districts; public housing authorities/Indian housing authorities; special district and regional organizations; and for-profit organizations (including small businesses and other for-profit entities). Eligible federal agencies are also noted.
Are minority-serving and community/faith-based organizations eligible?
The announcement explicitly notes eligibility for institution types such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian Serving Institutions, Tribally Controlled Colleges and Universities, and faith-based or community-based organizations.
Are non-U.S. (foreign) institutions eligible to apply?
No. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply.
Are foreign components allowed in any form?
Yes. The FOA indicates that foreign components (as defined in NIH policy) are allowed. This generally means discrete project elements or collaborations occurring outside the U.S. can be included when justified and consistent with NIH rules.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
What CFDA numbers are associated with this opportunity?
The opportunity aligns with CFDA 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
When was the FOA posted and when did it close?
The FOA was posted February 3, 2014, and the closing date was September 18, 2014.
What does it mean that the FOA was archived?
The FOA was archived October 19, 2014, indicating the opportunity is no longer active as a current open solicitation.
How much funding was estimated for the program?
Total estimated funding was listed as $15,700,000.
What was the award ceiling?
The award ceiling was listed as $2,120,000.
Does the funding structure suggest multiple awards?
Yes. The combination of total estimated funding and an award ceiling indicates support for multiple awards and multi-component projects typical of U19 consortium structures.
What disease areas are the best fit for this FOA?
The FOA is positioned as a human immunology initiative focused on infectious disease and vaccinology in non-HIV settings, aiming to connect immune profiling with clinically meaningful outcomes.
What makes a strong application conceptually, based on the FOA description?
The FOA highlights the value of well-characterized human cohorts; deep clinical and demographic data; high-throughput, systems-level immune profiling; integrative computational analysis; and an ability to work in a coordinated consortium with shared standards and rapid data sharing.
Browse more opportunities from the same category: Health
Next opportunity: DE FOA 0000996 RENEWABLE CARBON FIBERS
Previous opportunity: Desalination and Water Purification Research and Development (DWPR) Pre proposal Solicitation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 14 007
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 14 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Black Lung Clinics Grant Program Apply for HRSA 14 045 Funding Number: HRSA 14 045 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Black Lung Centers of Excellence Apply for HRSA 14 118 Funding Number: HRSA 14 118 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Affordable Care Act Patient Centered Medical Home Facility Improvements (P FI) Grant Program Apply for HRSA 14 073 Funding Number: HRSA 14 073 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Hemoglobinopathies Surveillance, Health Promotion, and Laboratory Capacity Demonstration Project DD12 1206 Apply for CDC RFA DD14 1408 Funding Number: CDC RFA DD14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Ryan White HIV/AIDS Program National Training and Technical Assistance Cooperative Agreements Establishing AIDS Service Organization Service Models and Engaging in Marketplace Insurance Plans under the Affordable Care Act Apply for HRSA 14 102 Funding Number: HRSA 14 102 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| State Based Public Health Laboratory Biomonitoring Programs Apply for CDC RFA EH14 1402 Funding Number: CDC RFA EH14 1402 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| National Rural Health Policy and Community Development Program Apply for HRSA 14 080 Funding Number: HRSA 14 080 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Improving Access to Eye Care among Persons at High Risk of Glaucoma Apply for RFA DP 14 002 Funding Number: RFA DP 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,300,000 |
| Emerging Infectious Disease Detection in the Veterinary Public Health Sector in India Apply for RFA GH 14 004 Funding Number: RFA GH 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| Comprehensive Care for Children Affected by HIV and AIDS (C3) Apply for RFA OAA 14 000005 Funding Number: RFA OAA 14 000005 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| Alzheimers Disease Pilot Clinical Trials (R01) Apply for PAR 14 089 Funding Number: PAR 14 089 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| PROJECT SOAR DRAFT FOR COMMENTS Apply for RFA OAA GH DRAFT PS Funding Number: RFA OAA GH DRAFT PS Agency: Agency for International Development Category: Health Funding Amount: $70,000,000 |
| NIDCD Research on Hearing Health Care (R21) Apply for PA 14 090 Funding Number: PA 14 090 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| NIDCD Research on Hearing Health Care (R01) Apply for PA 14 091 Funding Number: PA 14 091 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Health Information Technology (HIT) Capacity Building for Monitoring and Improving Health Outcomes Along the HIV Care Continuum Technical Assistance Center Apply for HRSA 14 088 Funding Number: HRSA 14 088 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement for the Historically Black Colleges and Universities (HBCU) Center for Excellence in Behavioral Health (HBCU CFE) Apply for TI 14 006 Funding Number: TI 14 006 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $500,000 |
| Emerging Pandemic Threats One Health Workforce Apply for RFI EPT 2 OHW Funding Number: RFI EPT 2 OHW Agency: Agency for International Development Category: Health Funding Amount: $50,000,000 |
| Longitudinal Study of a Population based Cohort of People with Lupus Apply for RFA DP 14 004 Funding Number: RFA DP 14 004 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Emerging Pandemic Threats Program PREDICT 2 Apply for RFI EPT 2 PREDICT 2 Funding Number: RFI EPT 2 PREDICT 2 Agency: Agency for International Development Category: Health Funding Amount: $100,000,000 |
| Emerging Pandemic Threats Program Prepare and Respond Apply for RFI EPT 2 PR Funding Number: RFI EPT 2 PR Agency: Agency for International Development Category: Health Funding Amount: $45,000,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 14 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.